OmniAb
Antibody discovery company.
Launch date
Employees
Market cap
€484m
Enterprise valuation
€455m (Public information from Sep 2024)
Share price
$4.73 OABI
Emeryville California (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 23.3m | 34.7m | 59.1m | 34.2m | 31.2m | 54.1m | 70.6m |
| % growth | 27 % | 49 % | 70 % | (42 %) | (9 %) | 73 % | 30 % |
| EBITDA | (10.6m) | (18.1m) | (13.0m) | (49.9m) | (50.9m) | (34.2m) | (6.6m) |
| % EBITDA margin | (45 %) | (52 %) | (22 %) | (146 %) | (163 %) | (63 %) | (9 %) |
| Profit | (17.6m) | (27.0m) | (22.3m) | (50.6m) | (59.5m) | (42.6m) | (29.1m) |
| % profit margin | (75 %) | (78 %) | (38 %) | (148 %) | (191 %) | (79 %) | (41 %) |
| EV / revenue | - | - | 5.5x | 21.0x | 15.9x | 9.2x | 7.0x |
| EV / EBITDA | - | - | -25.0x | -14.4x | -9.7x | -14.5x | -75.0x |
| R&D budget | 24.8m | 39.2m | 48.4m | 56.5m | - | - | - |
| R&D % of revenue | 107 % | 113 % | 82 % | 165 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
$35.5m Valuation: $35.5m | Acquisition | ||
* | N/A | Spinout | |
* | $115m Valuation: $850m 24.5x EV/LTM Revenues -47.0x EV/LTM EBITDA | SPAC Private Placement | |
* | $230m Valuation: $850m 24.5x EV/LTM Revenues -47.0x EV/LTM EBITDA | SPAC IPO | |
* | N/A | N/A | Post IPO Equity |
| Total Funding | €105m | ||
